Telix and ITM agree $1.65bn radiopharmaceutical merger
Telix Pharmaceuticals has agreed to acquire ITM in a major radiopharmaceutical transaction valued at $1.65 billion upfront, with up to a further $700 million linked to regulatory and commercial milestones.
The combination brings together Telix's oncology-focused radiopharmaceutical portfolio with ITM's isotope production infrastructure and therapeutic development capabilities.
The transaction is intended to create a larger vertically integrated radiopharmaceutical company with capabilities spanning isotope supply, drug development, manufacturing and commercialisation.
Field | Content |
Alert Type | Deal |
Companies | Telix Pharmaceuticals; ITM |
Deal Type | Acquisition |
Asset or Company | ITM |
Therapy Area(s) | Oncology; nuclear medicine |
Technology or Modality | Radiopharmaceuticals; radioligand therapy; medical isotopes |
Deal Value | US$1.65 billion upfront on a cash-free/debt-free basis, plus up to US$700 million in contingent regulatory and commercial milestone payments |
Geography | Global |
What Happened | Telix agreed to acquire 100% of ITM in a transaction valued at US$1.65 billion upfront, with additional contingent payments linked to ITM-11. |
Why It Matters | The transaction combines a commercial and clinical radiopharmaceutical portfolio with major isotope-production capabilities, increasing scale across the radiopharma value chain. |
Supporting Context | ITM has established isotope-production infrastructure and a pipeline of radiopharmaceutical therapies, while Telix has built a growing portfolio of diagnostic and therapeutic nuclear-medicine products. |
Strategic Rationale | Telix gains greater control over isotope supply, manufacturing and therapeutic development while expanding its oncology pipeline and global radiopharmaceutical infrastructure. |
Potential Impact | The combined business could improve isotope security, accelerate development of new radioligand therapies and strengthen competition in the rapidly expanding radiopharmaceutical market. |
Key Takeaway | Telix is acquiring ITM for US$1.65 billion upfront in a major transaction designed to create a vertically integrated global radiopharmaceutical company. |
What to Watch | Regulatory approvals, transaction completion, integration of isotope-production operations and progress of ITM-11 against its contingent milestones. |
Primary Source | Telix Pharmaceuticals |
Relevant Date | 21 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare